| Website | adimab.com |
| Category | BioTech |
| Phone | (603) 727-7107 |
| info@adimab.com | |
| Employees | 60 |
| Founded | 5/07 |
| Description | monoclonal antibody discovery platform |
| TOTAL | $39.7M |
| FUNDING TOTAL | $39.7M |
| Series A, 7/07 | $400k |
| Venture Round, 7/07 | $2.38k |
| Series A, 9/07 Polaris Partners SV Life Sciences | $5.9M |
| Series B, 4/08 | $3.18M |
| Series C, 11/08 OrbiMed Advisors Borealis Ventures Polaris Partners SV Life Sciences | $4M |
| Series D, 1/10 Google Ventures OrbiMed Advisors Borealis Ventures Polaris Partners SV Life Sciences | $8.2M |
| Venture Round, 12/10 | $4M |
| Series F, 4/12 | |
| Venture Round, 4/12 Google Ventures Polaris Partners SV Life Sciences | $14M |
Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.